Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.
If we see the Prospective Resources turn to Contingent Resources following the release of the 3d seismic reprocessing of Chuditch then we will see a major re-rate imo.
Hard to say. Based on the assets they are significantly undervalued. If management sort themselves out then we could be looking at a serious re-rate here with the oil price at where it is coupled with the positive news from Nigeria yesterday regarding the oil bill.
From the last RNS on rhe director changes and the appointment of Dr. D'Attanasio.
'Funds managed by Hadron Capital are a shareholder of the Company and as such will not be an independent non-executive director.'
Any sign of funding for Otakikpo and we should see a good rise here. Bearing in mind it is just $10million needed to boost production to 10,000 bopd this should be fairly easy to find. On top of this there is OPL 310 with a oil discovery of 774 mmboe (232 mmboe net to Lek Oil) and OPL 325 exploration asset with potential 5.7 billion barrels. With Metallon now on the board and the oil price recovery, Lek seem significantly undervalued.
Purely from a balance sheet perspective Lek OIl have $166 million net assets as opposed to a market cap of £13 million. With the oil price performing well this as got to be one of the most undervalued stocks around.
Asian LNG price just hit an all time high which could explain the rise. Coro's stake in the Mako gas field is starting to look extremely valuable.
Posted on ii
Interesting article on Lixus from p64 for those interested in the science. Last para particularly encouraging:
“Recent PSDM reprocessing of the vintage dataset is further de-risking discovered and prospective resources within the proven Miocene gas play, as well as opening new play systems for gas in the Pliocene and for oil in the sub-nappe section through the significant improvements in deep imaging. With proven resources ready for commercialization and long-term growth opportunities through a diverse set of exploration plays, the high potential of this area is only just starting to be fully resolved.”
https://www.google.com/url?sa=t&source=web&rct=j&url=https://assets.geoexpro.com/uploads/667e7f1b-e131-4e88-b54d-8a41454628a4/Geoscience_Magazine_GEO_ExPro_v17i2.pdf&ved=2ahUKEwiwm5ze4cnpAhWDShUIHbEgCbAQFjAFegQIAhAB&usg=AOvVaw3IdooGurgv8lNkxwPOeuQD 3
Yes it is certainly looking good over the next few months hangs2left. As far as I can see this is by far the cheapest Covid 19 play on the market. This is understandable as N4P are the end point where the focus has been on testing and the actual vaccine. This will soon change and all the attention will start to shift to companies like N4P which should stand us in good stead. It's going to be an exciting few months.
Absolutely Zwartkops. We are approaching an unprecedented situation where the whole world will be requiring a vaccine. It's a perfect scenario for N4 Pharma to show the capabilities of Nuvec. Anyway you look at this it just seems that a significant rise is inevitable at some point.
This could turn into a very interesting Covid play. Not the traditional stocks of testing or adapting existing drugs to find a vaccine we have seen. Being involved in the next stage of the vaccine delivery will be the next point of interest and with N4P potentially having the technology to do this puts us in an exciting position. With Evotec on board the market hasn't yet noticed the potential here. I feel like a significant re-rate is coming over the next few months.